Core Viewpoint - The company has developed a comprehensive plan to advance its VC project technical upgrades without affecting normal production capacity and market supply [2] Group 1 - The company is committed to enhancing overall profitability through lean production and optimized market strategies [2]

Core Viewpoint - The announcement by the National Health Commission regarding the approval of new food materials, including the protein from the fungus Veneta, signifies a regulatory milestone for the company, allowing its subsidiary to produce and sell this new food ingredient domestically [1] Company Summary - Fujian Pharmaceutical (300497.SZ) announced that its subsidiary, Jiangxi Fujian Biotechnology Co., has successfully obtained administrative approval for the new food material application of Veneta fungus protein from the National Health Commission [1] - The approval indicates that the safety assessment materials submitted for Veneta fungus protein have been reviewed and passed by expert organizations [1] Industry Summary - The approval of Veneta fungus protein as a new food material aligns with the regulatory framework established by the Food Safety Law, highlighting the increasing acceptance of innovative food ingredients in the market [1] - This development may open new avenues for the production and commercialization of alternative protein sources within the food industry [1]

Core Viewpoint - The National Health Commission of China has approved the safety assessment of the new food ingredient, Venetian Sclerotium Protein, as part of its announcement regarding 14 new food items [1] Group 1 - The announcement is documented as No. 7 of 2025 by the National Health Commission [1] - The approval follows a review of safety assessment materials submitted for the new food ingredient [1] - The review was conducted by expert evaluators organized by the National Health Commission [1]

证券代码：300497 证券简称：富祥药业 公告编号：2025-075 特此公告。 江西富祥药业股份有限公司 近日，国家卫生健康委员会（以下简称"国家卫健委"）发布了《关于威尼斯镰 刀菌蛋白等14种"三新食品"的公告》（2025年第7号），根据《中华人民共和国食 品安全法》规定，国家卫健委审评机构组织专家对威尼斯镰刀菌蛋白物质申请新食品 原料的安全性评估材料进行审查并通过。 该项公告的发布，标志着由江西富祥药业股份有限公司（以下简称"公司"）子 公司江西富祥生物科技有限公司（以下简称"富祥生物"）向国家卫健委提出的关于 威尼斯镰刀菌蛋白新食品原料行政许可审批获得通过，富祥未冉蛋白将可作为新食品 原料在国内进行生产、销售，有利于公司全面加速国内未冉蛋白商业化布局，保障国 家粮食供给安全，助力实现"双碳"目标，同时满足我国日益增长的高质量蛋白需求。 富祥未冉蛋白已取得中国、美国、新加坡、欧洲等国家有关部门认证，为其全球化商 业运用奠定了坚实基础。 富祥生物已具备年产1200吨微生物蛋白（未冉蛋白）生产能力，成为国内首家实 现未冉蛋白千吨级产业化企业。且正在加速建设年产20万吨微生物蛋白（未冉蛋白） 及资源综合利用 ...

证券日报网讯11月27日，富祥药业（300497）在互动平台回答投资者提问时表示，近期锂电池电解液添 加剂VC、FEC产品价格回升，对公司业绩存在积极影响。公司将积极把握锂电池电解液添加剂产品价 格上涨的市场机遇，同时依托医药制造业务的成本改善、微生物蛋白业务的战略推进，努力提升整体盈 利能力。 ...

证券日报网讯11月27日，富祥药业（300497）在互动平台回答投资者提问时表示，目前公司VC、FEC 产线稳健运行，生产经营正常，依据客户订单有序交付。 ...

Market Overview - On November 27, the A-share market experienced a pullback after an initial rise, with the Sci-Tech 50 and ChiNext indices both retreating over 2% from their gains, while the Shanghai Composite Index rose by 0.29% and the Shenzhen Component Index fell by 0.25% [2][3]. Sector Performance - The organic silicon, solid-state battery, consumer electronics, paper, and photovoltaic equipment sectors showed strong performance, while sectors such as Hainan Free Trade Zone, film and television, cultivated diamonds, China Shipbuilding Industry, and internet e-commerce saw declines [2][3]. - Notably, organic silicon stocks surged, with companies like Hongbo New Materials and Chenguang New Materials hitting the daily limit, and Huasheng Lithium Battery, Jinyin Galaxy, and Yuanxiang New Materials rising over 10% [2][3]. Key Stocks - Solid-state battery stocks saw a wave of limit-ups, with companies like Mingguan New Materials, Liande Equipment, Haike New Source, and Huazi Technology all reaching the daily limit [5]. - Specific stock performances included: - Huaguan Lithium Battery: +15.54% at 115.86 - Jinyin Galaxy: +12.96% at 51.08 - Yuanxiang New Materials: +11.03% at 47.21 - Hongbo New Materials: +10.05% at 7.23 - Chenguang New Materials: +9.97% at 15.99 [4][5]. Capital Flow - Main capital flows indicated a net inflow into sectors such as consumer electronics, paper printing, and batteries, while there was a net outflow from cultural media, communications, and computing sectors [7][8]. - Notable net inflows were seen in stocks like ZTE Corporation, Chip Original, and Furi Electronics, with inflows of 0.787 billion, 0.488 billion, and 0.463 billion respectively [7]. - Conversely, stocks like Zhongji Xuchuang, Hudian Co., and Ningde Times faced significant sell-offs, with outflows of 1.446 billion, 0.967 billion, and 0.789 billion respectively [8]. Institutional Insights - Debon Securities noted that market volume will determine the height of the market trend, suggesting a continued rotation between technology and consumer sectors [9]. - Hengsheng Qianhai Fund highlighted that the A-share market remains in a state of strong bullish and bearish sentiment, with expectations of continued volatility [10]. - Dongwu Securities emphasized the robust demand for computing power within the industry chain, indicating that the market for computing infrastructure is still in a phase of rapid expansion [10].

格隆汇11月27日丨富祥药业(300497.SZ)在投资者互动平台表示，目前公司VC、FEC产线稳健运行，生 产经营正常，依据客户订单有序交付。 ...

Group 1 - The company confirmed that its VC and FEC production lines are operating steadily and that production and operations are normal [2] - The company is delivering products in an orderly manner based on customer orders [2]

Core Points - The company, Fujian Pharmaceutical Co., Ltd., has recently obtained the Good Manufacturing Practice (GMP) certification from the Brazilian National Health Surveillance Agency (ANVISA) for its chemical raw material, Tazobactam [1] Group 1 - The certification signifies compliance with international quality standards for pharmaceutical production [1] - The scope of the certification specifically covers the production of Tazobactam, which is a key pharmaceutical ingredient [1]